According to Fortune Business Insights, the global cell therapy market size was valued at USD 8.64 billion in 2025. The market is projected to grow from USD 12.22 billion in 2026 to USD 122.87 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 33.14% during the forecast period of 2026–2034. North America dominated the market with a 47.10% share in 2025, supported by established healthcare infrastructure, extensive research and development activities, and the availability of commercially approved cell-based treatments.
The cell therapy market is experiencing significant expansion as healthcare providers increasingly explore advanced treatments for diseases that have limited therapeutic options. Commercially available products, particularly chimeric antigen receptor T-cell (CAR-T) therapies, have established an important foundation for market growth.
According to Fortune Business Insights, the CAR-T cell therapy segment accounted for 99.8% of the market share in 2025. Its leadership reflects increasing clinical adoption, a strong product pipeline, and continued investment in engineered cellular treatments. Oncology remains the principal application area, while hospitals and clinics represent the leading end-user segment.
However, the market faces several challenges, including high treatment costs, complex manufacturing processes, patient-specific production requirements, and potential safety complications. Addressing these barriers will be essential for expanding access and supporting sustainable long-term growth.
For detailed market insights: https://www.fortunebusinessinsights.com/cell-therapy-market-114224
One of the major trends in the cell therapy market is the expansion of research beyond blood cancers into solid tumors. Companies are developing engineered T-cell therapies designed to recognize specific tumor-associated targets and address challenges such as cancer-cell resistance and antigen escape.
The U.S. Food and Drug Administration's approval of AMTAGVI (lifileucel) in February 2024 for advanced melanoma demonstrated progress in cellular immunotherapy for solid tumors. Such developments are encouraging further research into new cancer indications.
Allogeneic cell therapies use cells obtained from donors rather than collecting and modifying each patient's own cells. These treatments may support more standardized manufacturing, improved scalability, and faster treatment availability.
Researchers and biotechnology companies are investigating donor-derived cellular platforms to reduce production complexity and potentially lower costs. Continued clinical development and advances in genetic engineering could strengthen the commercial prospects of these therapies.
Cell therapies require specialized production, quality control, storage, and distribution systems. Consequently, companies are investing in advanced manufacturing facilities and collaborative development infrastructure to improve production efficiency and support commercialization.
The need for more effective treatments for cancer and rare diseases is a major driver of market growth. Cell therapies can provide targeted treatment options for patients whose conditions have not responded adequately to conventional approaches. Their potential for durable clinical responses has increased interest among healthcare professionals, researchers, and pharmaceutical companies.
Regulatory approvals and accelerated development pathways are helping promising cellular treatments reach eligible patients. New product approvals and expansions into additional indications can increase treatment availability and strengthen commercial opportunities.